Vaxcyte Inc (NAS:PCVX)

$ 102.7 -1.37 (-1.32%) Market Cap: 12.80 Bil Enterprise Value: 10.82 Bil PE Ratio: 0 PB Ratio: 3.79 GF Score: 40/100

Q4 2023 Vaxcyte Inc Earnings Call Transcript
Feb 27, 2024

$81.05 (+2.63%)

Earnings
Vaxcyte Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Vaxcyte Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Vaxcyte Inc VAX-24 Phase 2 65+ Adult Study Results Call Transcript
Apr 17, 2023
Q4 2022 Vaxcyte Inc Earnings Call Transcript
Feb 27, 2023

$42.3 (+1.44%)

Earnings
Vaxcyte Inc VAX-24 Phase 1/2 Proof-of-Concept Study Topline Data Call Transcript
Oct 24, 2022
Vaxcyte Inc at Bank of America Healthcare Conference Transcript
May 10, 2022
Vaxcyte Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Q4 2021 Vaxcyte Inc Earnings Call Transcript
Feb 28, 2022

$23.17 (+2.52%)

Earnings
Vaxcyte Inc at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript
Oct 05, 2021
Vaxcyte Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021
Q4 2020 Vaxcyte Inc Earnings Call Transcript
Mar 29, 2021

Earnings

Vaxcyte Inc VAX-24 Phase 2 65+ Adult Study Results Call Transcript

Apr 17, 2023 / 11:30AM GMT

Release Date Price: $42.34 (+16.00%)

Transcript

Operator

Good morning. My name is Ashley, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte conference call to discuss the VAX-24 Phase II adult program, including the Phase II study results in adults aged 65 and older. (Operator Instructions) I would now like to turn the call over to Andrew Guggenhime, Chief Financial Officer of Vaxcyte. Please go ahead, sir.

Andrew L. Guggenhime

Vaxcyte, Inc. - President & CFO

Thank you, Ashley, and good morning, everyone. I'd like to welcome you to Vaxcyte conference call to discuss data from our Phase II study evaluating the safety, tolerability and immunogenicity of VAX-24, the company's investigational 24-valent pneumococcal conjugate vaccine in healthy adults aged 65 and older.

Additionally, we will be discussing full 6-month safety data from the adult Phase I/II and Phase II study as well as the prespecified pooled immunogenicity analyses of data from both adult Phase II studies.

I'm joined today by our Chief Executive Officer, Grant Pickering; and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.